Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, PR China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China.
Key Laboratory of Advanced Drug Preparation Technologies (Zhengzhou University), Ministry of Education, PR China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China; Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, PR China; Key Laboratory of Henan Province for Drug Quality and Evaluation, PR China.
Eur J Med Chem. 2017 Sep 29;138:1034-1041. doi: 10.1016/j.ejmech.2017.07.039. Epub 2017 Jul 22.
A series of thiazolo[5,4-d]pyrimidine derivatives were designed through the atom replacement strategy based on biologically validated scaffolds and then evaluated for their antiproliferative activities on cancer cell lines. The structure-activity relationship studies were conducted, leading to the identification of compound 22, which exhibited good antiproliferative activity against HGC-27 with an IC value of 1.22 μM and low toxicity against GES-1 cells. Mechanistic studies showed that compound 22 inhibited the colony formation and migration of HGC-27 as well as induced apoptosis. The western blot experiments proved that compound 22 up-regulated expression of Bax, down-regulated expression levels of Bcl-2 and cleaved caspased-3/9. These findings indicate that compound 22 may serve as a template for designing new agents for the treatment of human gastric cancers. The atom replacement strategy could be viable strategy for designing new anticancer drugs and may find its applications in drug design.
通过基于生物验证支架的原子替换策略设计了一系列噻唑并[5,4-d]嘧啶衍生物,并对其在癌细胞系中的抗增殖活性进行了评估。进行了构效关系研究,确定了化合物 22,其对 HGC-27 的抑制增殖活性良好,IC 值为 1.22 μM,对 GES-1 细胞的毒性低。机制研究表明,化合物 22 抑制 HGC-27 的集落形成和迁移,并诱导细胞凋亡。Western blot 实验证明,化合物 22 上调 Bax 的表达,下调 Bcl-2 的表达水平,并切割 caspase-3/9。这些发现表明,化合物 22 可能成为设计治疗人类胃癌新药物的模板。原子替换策略可能是设计新型抗癌药物的可行策略,并可能在药物设计中得到应用。